IDENIX PHARMACEUTICALS INC 4

Accession 0001104659-12-012152

CIK 0001093649operating

View on SEC.gov Company Profile

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 4:18 PM ET

Size

36.0 KB

Accession

0001104659-12-012152

Insider Transaction Report

Form 4

Period: 2012-02-23

IDENIX PHARMACEUTICALS INCIDIX

NOVARTIS AG

Other

Transactions

Purchase
Common Stock
2012-02-23$2.56/sh+2,493$6,382→ 33,274,375 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.85/sh+1,321$3,765→ 33,277,690 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.90/sh+3,117$9,039→ 33,280,807 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.97/sh+427$1,268→ 33,290,194 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.10/sh+39$199→ 33,297,894 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.46/sh+7,402$40,415→ 33,316,729 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.41/sh+35,735$86,121→ 33,271,516 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$6.52/sh+493$3,214→ 33,318,541 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$7.39/sh+2,133$15,763→ 33,320,674 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.78/sh+997$2,772→ 33,276,369 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.96/sh+8,960$26,522→ 33,289,767 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.47/sh+366$904→ 33,271,882 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.69/sh+997$2,682→ 33,275,372 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.04/sh+232$705→ 33,290,426 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.11/sh+11,433$58,423→ 33,309,327 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.80/sh+436$2,529→ 33,318,048 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.17/sh+4,336$13,745→ 33,294,762 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.79/sh+3,093$11,722→ 33,297,855 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.79/sh+883$5,113→ 33,317,612 total(indirect: See Footnote)

NOVARTIS PHARMA AG

10% Owner

Transactions

Purchase
Common Stock
2012-02-23$2.41/sh+35,735$86,121→ 33,271,516 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.69/sh+997$2,682→ 33,275,372 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.78/sh+997$2,772→ 33,276,369 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.96/sh+8,960$26,522→ 33,289,767 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.17/sh+4,336$13,745→ 33,294,762 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.79/sh+883$5,113→ 33,317,612 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$7.39/sh+2,133$15,763→ 33,320,674 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.47/sh+366$904→ 33,271,882 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.90/sh+3,117$9,039→ 33,280,807 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.11/sh+11,433$58,423→ 33,309,327 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.80/sh+436$2,529→ 33,318,048 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$6.52/sh+493$3,214→ 33,318,541 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.97/sh+427$1,268→ 33,290,194 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.79/sh+3,093$11,722→ 33,297,855 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.10/sh+39$199→ 33,297,894 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$5.46/sh+7,402$40,415→ 33,316,729 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.56/sh+2,493$6,382→ 33,274,375 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$2.85/sh+1,321$3,765→ 33,277,690 total(indirect: See Footnote)
Purchase
Common Stock
2012-02-23$3.04/sh+232$705→ 33,290,426 total(indirect: See Footnote)

Footnotes (1)

[F1]These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is indirect beneficial owner of these securities. See attachment.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

IDENIX PHARMACEUTICALS INC

CIK 0001093649

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001093649

Filing Metadata

Form type: 4
Filed: Feb 22, 7:00 PM ET
Accepted: Feb 23, 4:18 PM ET
Size: 36.0 KB

View on SEC.gov